NSC194598

NSC194598 (1-2 μM; 35 min) inhibits p53, p63γ, and p73β DNA binding^[1].
NSC194598 inhibits the DNA-binding activity of p53-Cluc in a cell-free luciferase fragment competition assay with an IC₅₀ of 0.18 μM^[1].
NSC194598 inhibits a p53 quadruple mutant (p53-
M133L/V203A/N239Y/N268D) with an IC₅₀ of 0.06 μM^[1].
NSC194598 (2-40 μM; 4 h) inhibits IR-induced p53 DNA binding and target gene expression in U2OS cells^[1].
NSC194598 (2-40 μM; 8 h) inhibits p21 induction by activated p53^A138V in H1299-p53^A138V cells without altering p53 levels^[1].
NSC194598 (5-20 μM; 32 h) causes weak p53 accumulation and p21 induction in SJSA cells, and inhibits Nutlin-induced p21 expression^[1].
NSC194598 (0.5-20 μM) stabilizes the wild-type RET promoter G-quadruplex structure without altering its parallel folding pattern^[2].
NSC194598 (0.6-2.5 μg/mL; 24 h) inhibits wild-type RET promoter-driven luciferase activity in HEK293 WT cells by over 60% after 24 h treatment at 2.5 μg/mL, with concentration-dependent effects^[2].
NSC194598 (1.2-2.5 μg/mL; 24-48 h) reduces RET mRNA expression in TT cells^[2].
NSC194598 (2.5 μM; 24 h) inhibits recruitment of RNA polymerase II, Sp1, and nucleolin to the RET promoter at 2.5 μM for 24 h in TT cells^[2].
NSC194598 (0.3-2.5 μg/mL; 24 h) reduces TT cell growth and increases caspase 3 activity^[2].
NSC194598 (0.6-2.5 μg/mL; 24 h) induces dose-dependent increases in late apoptotic/necrotic TT cells, and induces G0/G1 phase arrest^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.